Performance of fracture risk assessment tool in HIV‐positive male individuals aged ≥45 years on suppressive antiretroviral therapy

• Published in: Journal of the International AIDS Society 2019-08, Vol.22 (8), p.e25383-n/a
• Main Authors: Tsai, Mao‐Song, Zhang, Jun‐Yu, Sun, Hsin‐Yun, Liu, Wen‐Chun, Wu, Pei‐Ying, Yang, Chia‐Jui, Hung, Chien‐Ching
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Adult; Age; ageing; AIDS; Algorithms; Anti-HIV Agents - therapeutic use; Antiretroviral drugs; Bone Density; bone mineral density; combination antiretroviral therapy; Cross-Sectional Studies; Data collection; Drug therapy; Fractures; Fractures, Bone - etiology; Hip Fractures - etiology; HIV; HIV Seropositivity - complications; HIV Seropositivity - drug therapy; HIV Seropositivity - epidemiology; Human immunodeficiency virus; Humans; Laboratories; Male; Males; Middle Aged; osteopenia; Osteoporosis; Osteoporosis - etiology; Osteoporotic Fractures - etiology; Prevalence; Prevention; Questionnaires; Risk assessment; Risk Factors; Studies; Surveys and Questionnaires; Taiwan - epidemiology
• ISSN: 1758-2652; 1758-2652
• DOI: 10.1002/jia2.25383

Introduction An age‐specific evaluation and management algorithm for reduced bone mineral density (BMD) is suggested for HIV‐positive patients without major risk factors. Whether combination of BMD and the Fracture Risk Assessment Tool (FRAX) may detect more individuals for therapeutic interventions remains unclear. We aimed to determine the prevalence of middle‐aged or older HIV‐positive males fitting the criteria of therapeutic interventions with different approaches. Methods From July 2016 to February 2018, HIV‐positive male patients aged ≥45 years receiving suppressive antiretroviral therapy were recruited in a cross‐sectional study, at two designated hospitals for HIV care in northern Taiwan. Patients with malignancy, AIDS, pre‐existing bone disease or immobilization were excluded. Information on clinical and demographic characteristics, FRAX questionnaire, activity questionnaire, BMD and serum 25(OH)D was obtained. FRAX scores combined with BMD (FRAX/BMD) and without BMD (FRAX) were calculated. The data were analysed on the basis of major risk factors for fragility fracture and age stratification, FRAX score and BMD results respectively. Results We enrolled 330 patients with a mean age of 51.6 years and CD4 610 cells/μL, in whom 98.1% (n = 324) underwent BMD assessment of one site or more. By FRAX, 6.7% (n = 22) reached treatment thresholds (10‐year risk of major osteoporotic fracture ≥20% and/or hip fracture ≥3%). The prevalence of osteopenia (−2.5